Signalway Antibody (SAB) was founded in 2003 and is headquartered in College Park, Maryland, USA. It is a professional biotechnology enterprise that integrates research, production, and sales, committed to providing efficient and fast research tools for life science researchers worldwide. The company has 14 years of experience in the research and production of antibody reagents, and currently has over 90000 scientific research antibody products, including nearly 2000 characteristic phosphorylated and methyl/acetylated modified antibodies, over 18000 total antibodies, over 60000 labeled antibodies, commonly used labeled antibodies, and secondary antibodies. The products are widely used in life science research fields such as cell signal transduction, tumor research, neuroscience, and epigenetics. In addition to antibody products, SAB has also invested in the development of recombinant proteins/cytokines and ELISA kits in recent years, covering multiple species and different research fields. Currently, thousands of products have been launched. SAB products are sold to more than 40 countries around the world, including the United States, Canada, the United Kingdom, Germany, and Japan, and are highly welcomed and praised by major research institutions, universities, enterprises, and medical institutions such as NIH, MD Anderson Cancer Center, UCLA, Harvard, Stanford, etc. The products sold have been extensively published in top tier journals such as Cell, Nature, Science, PNAS, etc. As of now, thousands of SCI academic papers have cited SAB products
